Key Dates

Related Announcements

NOT-TR-23-023 - Notice of Early Termination of NOT-TR-21-017, Notice of Special Interest (NOSI): Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Center for Advancing Translational Sciences (NCATS)

Purpose

The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts.

NCATS is soliciting applications for Administrative Supplements (through PA-20-272) from current Clinical and Translational Science Award (CTSA) UL1 component award recipients from these FOAs:

• PAR-18-940 Clinical and Translational Science Award (U54 Clinical Trial Optional)
• PAR-18-464 Clinical and Translational Science Award (U54 Clinical Trial Optional)
• PAR-15-304 Clinical and Translational Science Award (U54 Clinical Trial Optional)
• RFA-TR-14-009 Clinical and Translational Science Award (U54 Clinical Trial Optional)

In addition, NCATS is soliciting applications for Administrative Supplements (through PA-20-272) from current Clinical and Translational Science Award (CTSA) U24 recipients from these FOAs:

• RFA-TR-17-006 CTSA Program Data to Health (CD2H) Coordinating Center (U24)
• RFA-TR-16-021 Coordination Center for the CTSA Program (U24)
• RFA-TR-15-002 CTSA Network - Trial Innovation Centers (TICs) (U24)
• RFA-TR-15-004 Clinical and Translational Science Award (CTSA) Network Recruitment Innovation Centers (RICs)(U24)

NCATS expects to issue 1-4 awards for involvement with clinical studies and trials in support of COVID interventions, as well as providing clinical samples and assessing infectious or convalescent status.

Award Project Period

The parent award must be active when the supplement application is submitted (e.g. within the originally reviewed and approved project period). The research proposed in the supplement should be requested for one year and should be accomplished within the currently approved project period for the existing parent award.

• The project period will generally be limited to 1 year. Project periods up to 2 years will be considered only with strong justification.
• The NCATS may consider on a case-by-case basis a no-cost extension for the supplement of up to an additional year at the conclusion of the first year, provided it is well justified and within the remaining parent project period.

Award Budget

Application budgets for these administrative supplements may exceed the amount of the current parent award with strong justification and must reflect the actual needs of the proposed project.

A letter must be submitted and approved by the program officer on your active award in advance if your application will request $500,000 or more in direct costs. If approved, the applicant must include a cover letter with the application indicating that NCATS will accept the application.

Description of circumstances for which administrative supplements are available.

Application and Submission Information

Applications in response to this NOSI must be submitted through the following target opportunity or subsequently reissued equivalents. Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissue of this announcement through the expiration date of this notice and designate NOT-TR-21-017 (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form as directed below.

• PA-20-272 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional), which is intended to provide additional funds for NIH grantees for work that falls within the scope of their active grant.

When developing applications in response to this NOSI, all instructions in theSF424 (R&R) Application Guide and in the target funding opportunity announcement (PA-20-272) must be followed, with the following additions:

• Applications will be accepted immediately and on a rolling basis through August 16, 2024 by 5:00 PM local time of the applicant organization. This NOSI expires on August 17, 2024. An application submitted in response to this NOSI that is received on August 17, 2024 or later, will be withdrawn. Applications will be considered for funding in FY21 and subsequent fiscal years through FY24 pending: award timelines, availability of funds, and programmatic priority.
• IMPORTANT: For funding consideration, all applicants must designate NOT-TR-21-017 (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form. Applications without this information in Box 4b will not be considered for this initiative.
• The Research Strategy section of the application is limited to 6 pages. Address assurances that the proposed project can be performed as described under the current Public Health Emergency circumstances.
• Recipients may apply for work that is related to your funded project.
• Follow the FOA Instructions for Electronic Application Submission through the NIH ASSIST system, an institutional system-to-system (S2S) solution, or Grants.gov workspace.
• The administrative supplement should be submitted electronically using the single component option. The single component option enables cooperative agreement mechanisms to submit electronically. Multi-components supplements cannot be submitted electronically at this time. Therefore, you must select the single component option when initiating the administrative supplement electronic application.
• Administrative supplement applications to PA-20-272 must use the application form package with the Competition ID that contains FORMS-E-ADMINSUPP . In addition, the process for Streamlined Submissions using the eRA Commons cannot be used for this initiative.
• Applications must specifically address issues of potential biohazards in the Research Strategy, and all research must be conducted in compliance with the health and safety requirements found in the NIH Grants Policy Statement.
• Funds awarded using special emergency appropriations provided by the Coronavirus Aid, Relief, and Economic Security (CARES) Act or the Coronavirus Response and Relief Supplemental Appropriations Act of 2021 (CRRSAA) will be issued in unique subaccounts in the HHS Payment Management System and will require separate financial reporting from any other funds awarded.

Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact the Grants Management Specialist on their active award to determine eligibility and the Program Officer on their active award to discuss the proposed project in the context of the parent award.

Applications that do not meet the requirements specified in this NOSI will be withdrawn from consideration for this initiative.

Inquiries

Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:

Scientific/Research Contact(s)

Please contact the program officer on your active award.

Financial/Grants Management Contact(s)

Please contact the grants specialist on your active award.